Title :

Scoring system for clinically significant cmv infection in seropositive recipients following allogenic hematopoietic cell transplant: an sfgm-tc study

Author(s) :

Beauvais, David [Auteur]
Drumez, Elodie [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Blaise, Didier [Auteur]
Peffault De Latour, Régis [Auteur]
Forcade, Edouard [Auteur]
Ceballos, Patrice [Auteur]
Uyttebroeck, Anne [Auteur]
Labussiere, Helene [Auteur]
Nguyen-Quoc, Stéphanie [Auteur]
Bourhis, Jean-Henri [Auteur]
Chevallier, Patrice [Auteur]
Thiebaut, Anne [Auteur]
Poire, Xavier [Auteur]
Maury, Sébastien [Auteur]
Deconinck, Eric [Auteur]
Cluzeau, Thomas [Auteur]
Brissot, Eolia [Auteur]
Huynh, Anne [Auteur]
Rubio, Marie-Thérèse [Auteur]
Duhamel, Alain [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Journal title :

Bone marrow transplantation

Abbreviated title :

Bone Marrow Transplant

Publication date :

2020-12-18

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

In order to identify cytomegalovirus (CMV)-seropositive patients who are at risk of developing CMV infection following first allogeneic hematopoietic cell transplantation (allo-HCT), we built up a scoring system based on ...
Show more >In order to identify cytomegalovirus (CMV)-seropositive patients who are at risk of developing CMV infection following first allogeneic hematopoietic cell transplantation (allo-HCT), we built up a scoring system based on patient/donor characteristics and transplantation modalities. To this end, 3690 consecutive patients were chronologically divided into a derivation cohort (2010-2012, n = 2180) and a validation cohort (2013-2014, n = 1490). Haploidentical donors were excluded. The incidence of first clinically significant CMV infection (CMV disease or CMV viremia leading to preemptive treatment) at 1, 3, and 6 months in the derivation cohort was 13.8%, 38.5%, and 39.6%, respectively. CMV-seropositive donor, unrelated donor (HLA matched 10/10 or HLA mismatched 9/10), myeloablative conditioning, total body irradiation, antithymocyte globulin, and mycophenolate mofetil significantly and independently affected the incidence of 3-month infection. These six factors were selected to build up the prognostic model. Four risk groups were defined: low, intermediate-low, intermediate-high, and high-risk categories, with a 3-month predicted incidence of first clinically significant CMV infection in the derivation cohort of 22.2%, 31.1%, 45.4%, and 56.9%, respectively. This score represents a framework for the evaluation of patients who are at risk of developing clinically significant CMV infection following allo-HCT. Prospective studies using this score may be of benefit in assessing the value of anti-CMV prophylaxis in well-defined patient cohorts.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2021-07-06T12:44:56Z